$697 Million is the total value of Soleus Capital Management, L.P.'s 72 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HCA | New | HCA HEALTHCARE INC | $8,290,618 | – | 34,550 | +100.0% | 1.19% | – |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $7,648,640 | – | 258,400 | +100.0% | 1.10% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $6,878,900 | – | 310,000 | +100.0% | 0.99% | – |
| AVTE | New | AEROVATE THERAPEUTICS INC | $6,361,587 | – | 217,119 | +100.0% | 0.91% | – |
| OFIX | New | ORTHOFIX MED INC | $6,062,509 | – | 295,300 | +100.0% | 0.87% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $5,656,887 | – | 254,700 | +100.0% | 0.81% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $5,599,000 | – | 220,000 | +100.0% | 0.80% | – |
| STAA | New | STAAR SURGICAL CO | $5,349,108 | – | 110,200 | +100.0% | 0.77% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $3,856,500 | – | 50,000 | +100.0% | 0.55% | – |
| BLI | New | BERKELEY LTS INC | $3,564,400 | – | 1,330,000 | +100.0% | 0.51% | – |
| PHVS | New | PHARVARIS N V | $3,487,500 | – | 310,000 | +100.0% | 0.50% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $3,421,000 | – | 31,100 | +100.0% | 0.49% | – |
| TGTX | New | TG THERAPEUTICS INC | $2,815,540 | – | 238,000 | +100.0% | 0.40% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $2,574,760 | – | 236,000 | +100.0% | 0.37% | – |
| TXG | New | 10X GENOMICS INC | $2,550,800 | – | 70,000 | +100.0% | 0.37% | – |
| New | VENTYX BIOSCIENCES INC | $2,262,510 | – | 69,000 | +100.0% | 0.32% | – | |
| NEOG | New | NEOGEN CORP | $2,185,505 | – | 143,500 | +100.0% | 0.31% | – |
| New | PARDES BIOSCIENCES INC | $2,112,500 | – | 1,250,000 | +100.0% | 0.30% | – | |
| PEN | New | PENUMBRA INC | $2,068,878 | – | 9,300 | +100.0% | 0.30% | – |
| LUNG | New | PULMONX CORP | $598,530 | – | 71,000 | +100.0% | 0.09% | – |
| KIDS | New | ORTHOPEDIATRICS CORP | $296,823 | – | 7,471 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.